Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 in Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma
NCT03793140Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in Burkitt lymphoma (BL), Burkitt leukemia, high grade B-cell lymphoma (HGBCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2018; status: completed.
02
Drugs
devimistat
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemiahigh grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03793140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793140.